CLLS: Prakiraan pendapatan perusahaan Cellectis SA

Cellectis (CLLS) - logo korporat

Risks are associated with ESG standard costs and biosafety requirements in the development of gene therapies. The target sales dynamics for Cellectis S.A. (CLLS) visualize these expenses, where 0.06 represents the latest metric reading. Stability is provided by TALEN patents and manufacturing complexity, as well as the company's status as a scientific pioneer in oncology, which guarantees long-term investor support.

Cellectis S.A. - Pendapatan mangsa ngarep perusahaan CLLS (periode 04.07.2022 - 13.11.2026)

Ringkesan rincian data analitis Cellectis Biotherapeutics (CLLS)

- nilai saham lan prakiraan konsensus rega:
Bagan rega Cellectis S.A.|CLLS - Bagan rega target
- informasi kapitalisasi pasar:
Nilai pasar Cellectis SA|CLLS - Nilai Total Perusahaan
- data ekuitas miturut neraca:
Nilai Akuntansi saben Saham Cellectis S.A.|CLLS - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku cellectis.com|CLLS - Aset Neraca Perusahaan
- statistik kawajiban utang lan likuiditas:
Total Utang marang Modal Cellectis S.A.|CLLS - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Cellectis S.A.|CLLS - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Cellectis SA|CLLS - Utang jangka dawa|Kewajiban jangka cendhak perusahaan Cellectis S.A.|Indikator likuiditas cepet cellectis.com
- rincian asil keuangan lan kelipatan valuasi:
CLLS - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Cellectis S.A.|CLLS - Nilai perusahaan marang bathi resik|Pangali Forward P/E Cellectis S.A.|CLLS - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Cellectis SA|CLLS - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Cellectis S.A.|CLLS - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan cellectis.com|CLLS - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Cellectis S.A.
- informasi babagan volume dodolan lan pendapatan:
CLLS - Total pendapatan perusahaan|Prakiraan volume dodolan Cellectis S.A.|CLLS - Kapitalisasi marang pendapatan|Multiplikator Forward P/S Cellectis SA
Ringkesan analitik perusahaan:Cellectis
Produk merek Cellectis S.A.

Fundamental screening of a defensive portfolio requires an analysis of projected cash flows, where the metric's calculation base is derived from expected revenue from future contracts and licensing agreements. For Cellectis S.A. (CLLS), whose pricing power is currently limited by the clinical trial stage, the company's potential sales volume reflects the value of its CAR-T patent portfolio, allowing investors to assess future commercial potential regardless of current market prices.

Pesaing Cellectis S.A. (CLLS)

Prakiraan pendapatan perusahaan Legend Biotech (LEGN)|Prakiraan pendapatan perusahaan SANA (sana.com)|Prakiraan pendapatan perusahaan Autolus Therapeutics plc AUTL|Allogene Therapeutics, Inc. - Prakiraan pendapatan perusahaan|RNAC: Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan CRBU (Caribou Biosciences, Inc)|TIL: Prakiraan volume dodolan|Prakiraan dodolan perusahaan Genenta Science GNTA|IPSC (Century Tx) - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Jasper Bio JSPR|Prakiraan pendapatan perusahaan Senti Biosciences, Inc. (SNTI)|adaptimmune.com - Prakiraan pendapatan perusahaan|Prakiraan volume dodolan CERO (CERo Therapeutics Holdings)|Alaunos Therapeutics Inc. (TCRT) - Volume dodolan sing dikarepake perusahaan|ACHL: Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan CRGX (CARGO Therapeutics Inc.)|PSTX (Poseida) - Volume dodolan mangsa ngarep perusahaan|TSVT: Prakiraan volume pendapatan perusahaan|GRCL (Gracell Biotechnologies) - Prakiraan volume dodolan